ASCO 2018: Oncology trials break new ground
Interviewee/Contributor
Bruno Pagliara
Research Directory
The myth of biotech self-determination
Interviewee/ContributorEdwin MosesOrganisationAblynx NVPharma slow to adopt SE incorporation
Interviewee/ContributorWilliam EllingtonOrganisationMedNousHow surrogate markers impact drug development
Interviewee/ContributorShiva MemariOrganisationVertical KnowingCurbing the use of unproven cellular therapies
Interviewee/ContributorMassimo DominiciOrganisationInternational Society Cell and Gene TherapyOwnership lessons for European biotechs
Interviewee/ContributorJohn RountreeOrganisationNovasectaSourcing antibiotics from the nematode worm
Interviewee/ContributorPhilippe Villain-GuillotOrganisationNosopharm SASInnovation spreads across the oncology sector
Interviewee/ContributorBruno PagliaraOrganisationOn-kòs Pharma ConsultingEuropean pharma plans new strategies for R&D
Interviewee/ContributorJean-Claude MullerOrganisationMedNousUsing nanotechnology to improve AIDS medication
Interviewee/ContributorPeter CharlishOrganisationMedNous